Last Seen Blogs
bagfulloflove
velvet cigarette
prcog
PR Cog's Tumblr Turnings
xandromedabbx
Ni De Aquí, Ni De Allá
hushed-chorus
gimme that vampire angst
Link
Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5) targeted pipeline therapeutics.
0 notes
Link
Biliary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Biliary Tumor pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Biliary Tumor, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
0 notes
Link
p38 MAP Kinase (EC 2.7.11.24) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on p38 MAP Kinase (EC 2.7.11.24) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
0 notes
Link
Interleukin 2 Receptor (IL2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Interleukin 2 Receptor (IL2R) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
0 notes
Link
Sodium/Glucose Cotransporter 1 (High Affinity Sodium-Glucose Cotransporter or Solute Carrier Family 5 Member 1 or SGLT1 or SLC5A1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Sodium/Glucose Cotransporter 1 (High Affinity Sodium-Glucose Cotransporter or Solute Carrier Family 5 Member 1 or SGLT1 or SLC5A1) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
0 notes
Link
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.
0 notes
Link
Malignant Neoplasms Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Malignant Neoplasms pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Malignant Neoplasms, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.
0 notes
Link
Epithelial Sodium Channel (ENaC or SCNN1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Epithelial Sodium Channel (ENaC or SCNN1) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
0 notes
Link
Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
0 notes
Link
Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Charcot-Marie-Tooth Disease Type I A pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I A, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.
0 notes
Link
Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
0 notes
Link
Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) targeted pipeline therapeutics.
0 notes
Link
5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on 5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
0 notes
Link
Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Stress Urinary Incontinence pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Stress Urinary Incontinence, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.
0 notes
Link
Cells Expressing Leukocyte Antigen CD37 (Tetraspanin 26 or CD37) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Cells Expressing Leukocyte Antigen CD37 (Tetraspanin 26 or CD37) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
0 notes
Link
Neuroendocrine Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Neuroendocrine Carcinoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neuroendocrine Carcinoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.
0 notes
Link
Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) targeted pipeline therapeutics. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
0 notes